Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
$6.91
-1.1%
$8.86
$5.85
$163.10
$25.54M0.9839,521 shs23,501 shs
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.47
+4.3%
$1.34
$7.80
$12.38
$25.36MN/A41,322 shs145,631 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.49
+1.4%
$1.41
$0.73
$2.70
$28.03M1.77788,202 shs209,564 shs
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
$2.42
+13.6%
$2.26
$1.30
$7.44
$7.66M0.15168,023 shs314,386 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
+1.45%+0.14%-20.02%-46.64%+698,999,900.00%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
-0.70%-6.00%+7.63%+16.53%-58.41%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+3.52%-3.92%+14.84%+10.53%-30.33%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
+2.40%+12.11%+1.43%+29.09%+1,027.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
0.1979 of 5 stars
0.02.00.00.03.00.00.0
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.3507 of 5 stars
3.82.00.00.03.10.00.6
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
0.00
N/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.50
Strong Buy$17.001,040.94% Upside
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
$470K53.66N/AN/A$2.91 per share2.37
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.05 per share27.08($0.53) per shareN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.13 per shareN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/A($0.37) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
-$7.32MN/A0.00N/AN/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%N/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
-$1.98MN/A0.00N/AN/AN/AN/A8/15/2025 (Estimated)

Latest NLSP, JATT, MIRA, and BDRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
0.01
1.75
1.75
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
12.86
12.86
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A
2.69
2.69

Institutional Ownership

CompanyInstitutional Ownership
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
17.51%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A

Insider Ownership

CompanyInsider Ownership
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
0.34%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
6.65%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
16.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
203.65 million3.64 millionNot Optionable
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
219.07 million17.80 millionNot Optionable
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
63.60 million3.01 millionNot Optionable

Recent News About These Companies

NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics, Kadimastem announce up to $3M equity financing
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics announces new preclinical data for AEX-2
NLS Pharmaceutics and Kadimastem complete pre-IND diabetes meeting with FDA
NLS Pharmaceutics files $75M mixed securities shelf
NLS Pharmaceutics files to sell 645,161 common shares for holders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biodexa Pharmaceuticals stock logo

Biodexa Pharmaceuticals NASDAQ:BDRX

$6.91 -0.08 (-1.14%)
Closing price 03:59 PM Eastern
Extended Trading
$7.12 +0.22 (+3.11%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.47 +0.06 (+4.26%)
As of 08/12/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.49 +0.02 (+1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 +0.01 (+0.34%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NLSP

$2.42 +0.29 (+13.62%)
Closing price 04:00 PM Eastern
Extended Trading
$2.43 +0.01 (+0.41%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.